Semaglutide

is prescribed to treat:

• Type 2 diabetes and weight management • Various related conditions in the diabetes category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist used for type 2 diabetes and, at higher doses, for obesity and weight management. It has reshaped both fields in a way few drugs do, because it produces weight loss of a magnitude previously achievable only with surgery, while also reducing cardiovascular events.

Mechanism of Action

Semaglutide mimics glucagon-like peptide-1, an incretin hormone released from the gut after eating. It acts on several tissues at once. In the pancreas it enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release — the glucose-dependence is important, because insulin release is stimulated only when blood sugar is elevated, which is why GLP-1 agonists rarely cause hypoglycemia on their own.

In the stomach it slows gastric emptying, prolonging satiety and blunting post-meal glucose rises. In the hypothalamus it acts on appetite-regulating centres, reducing hunger and food intake. The appetite effect, not the gastric effect, accounts for most of the weight loss, and patients frequently describe it as a reduction in food preoccupation rather than simple fullness.

Structural modifications give semaglutide a half-life of about a week, allowing once-weekly injection — a major adherence advantage over earlier daily agents such as liraglutide. An oral formulation exists but requires strict fasting administration for absorption.

Clinical Use

In type 2 diabetes, semaglutide lowers A1c substantially and is recommended irrespective of A1c in patients with established atherosclerotic cardiovascular disease, where it reduces major adverse cardiovascular events. It is typically added to metformin rather than replacing it. In obesity, at higher weekly doses, mean weight loss in trials has been in the range of 15 percent of body weight, far exceeding older pharmacotherapy.

Two practical realities shape outcomes. First, titration is slow and deliberate — dose escalation over months — because gastrointestinal side effects are dose-related and abrupt escalation is the main reason patients quit. Nausea, vomiting, constipation, and reflux are common early and usually attenuate; smaller meals, avoiding high-fat foods, and pausing escalation rather than abandoning treatment resolve most cases. The GLP-1 side effects article covers management in detail.

Second, weight regain after discontinuation is the rule rather than the exception, because the drug treats a chronic condition rather than curing it. Framing it as long-term therapy from the outset, like an antihypertensive, avoids the disappointment that follows an implicit expectation of a finite course.

Muscle mass loss accompanies rapid weight loss and deserves active attention — adequate protein intake and resistance training preserve lean mass and are worth prescribing alongside the drug. The visceral fat article explains why the distribution of loss matters as much as the amount. Our endocrine team supervises therapy alongside broader metabolic care, and the practice's GLP-1 program covers what supervised treatment involves.

Monitoring and Follow-Up

A1c is checked every three months until stable in diabetes; weight and waist circumference track response in obesity. Because semaglutide can reduce insulin and sulfonylurea requirements, those agents often need dose reduction at initiation to avoid hypoglycemia — the main setting in which a GLP-1 agonist contributes to low blood sugar.

Kidney function warrants attention during episodes of significant vomiting or diarrhea, since volume depletion can precipitate acute kidney injury. Semaglutide should be held during such illness. Pancreatitis has been reported, and severe persistent abdominal pain radiating to the back requires evaluation and drug cessation. Gallbladder disease occurs more frequently, largely as a consequence of rapid weight loss.

Diabetic retinopathy warrants a specific note: rapid improvement in glycemic control can transiently worsen retinopathy, so patients with existing significant retinopathy should have ophthalmologic assessment before and during treatment. The American Diabetes Association publishes patient-level guidance on where these agents fit.

Tirzepatide is the closest comparator and the question comes up constantly. It acts on both the GIP and GLP-1 receptors rather than GLP-1 alone, and in head-to-head trials it produced greater weight loss and greater A1c reduction than semaglutide. The side-effect profile is broadly similar. Neither is universally the right answer, since coverage, supply, injection schedule, and individual tolerance all differ, but a patient who has plateaued on maximum-dose semaglutide without reaching their goal has a reasonable alternative rather than having exhausted the class.

Special Populations

Semaglutide carries a boxed warning about thyroid C-cell tumours, based on rodent studies whose human relevance is unestablished. It is nonetheless contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

It should be discontinued before a planned pregnancy — typically two months in advance given the long half-life — and is not used during pregnancy or breastfeeding. Because it delays gastric emptying, it has implications for anaesthesia, and current guidance is to inform the anaesthesia team before any procedure requiring sedation. In older adults it is effective, but weight loss in the frail elderly is not universally desirable and muscle preservation matters more. Severe gastroparesis is a relative contraindication.

Access and continuity are genuine clinical issues with this drug, not just administrative ones. Supply shortages, insurance coverage that differs sharply between the diabetes and obesity indications, and compounded versions of uncertain content have all disrupted treatment. Interruptions matter more than with most drugs, because restarting after a long gap generally requires re-titrating from a low dose to avoid the gastrointestinal effects all over again. Compounded semaglutide is not FDA-approved and its content and purity are not verified; the FDA has warned specifically about compounded GLP-1 products. Planning around supply, and treating this as ongoing therapy rather than a course, avoids most of the disruption.

When to Contact Your Doctor

Seek prompt care for severe, persistent abdominal pain, particularly if it radiates to the back and is accompanied by vomiting, which may indicate pancreatitis. Report persistent vomiting or diarrhea causing reduced fluid intake, since dehydration and kidney injury follow. Right upper abdominal pain, fever, or jaundice may signal gallbladder disease. New or worsening vision changes need ophthalmologic assessment. A neck lump, difficulty swallowing, or persistent hoarseness should be reported. Tell any surgeon or anaesthetist that you take semaglutide before a procedure.

To discuss whether semaglutide is appropriate, manage side effects, or plan long-term treatment, contact us or schedule a visit.